Several studies have demonstrated improvement in treatment response by inclusion of a VEGF inhibitor in several cancer types, including breast cancer [45], NSCLC [46], metastatic colorectal cancer [47] and renal cell carcinoma [48]. This evidence concerns the gene VEGFA and renal cell carcinoma.